Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd. (603392.SH) has issued an announcement that its wholly-owned subsidiary, Wantai Canghai, recently received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for its freeze-dried recombinant respiratory syncytial virus vaccine (CHO cell).
The approval permits the launch of clinical trials to evaluate the vaccine's use in preventing lower respiratory tract disease caused by respiratory syncytial virus (RSV) infection in people aged 60 and above.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.